Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Cardiol Therapeutics (CT9) Stock Price & Analysis

0 Followers

CT9 Stock Chart & Stats

€0.84€0.04(5.40%)
At close: 5:30 PM GMT+1
€1€1.5Aug 10Aug 25Sep 9Sep 21Oct 6Oct 19Nov 5
Day’s Range
EUR 0.76 - EUR 0.84
52-Week Range
EUR 0.73 - EUR 1.95
Previous Close
EUR 0.80
Volume
N/A
Average Volume (3M)
406
Market Cap
EUR 108.09M
Enterprise Value
EUR 145.28M
Total Cash (Recent Filing)
EUR 26.08M
Total Debt (Recent Filing)
EUR 107.00K
Price to Earnings (P/E)
―
Beta
0.69
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.06
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low debt reduces financial risk and limits mandatory interest obligations while the company funds clinical development. This conservative leverage profile preserves flexibility to allocate capital toward research, trials, and regulatory work without a large debt burden.

Improving Net Loss

The reduction in annual net loss provides a modest indication that cost growth has not accelerated relative to the prior year. If maintained, better loss control could extend the usefulness of available capital and support more disciplined progression of the development pipeline.

Focused Clinical Pipeline

A focused pipeline targeting inflammatory and fibrotic heart diseases gives Cardiol a defined therapeutic strategy rather than a broad, unfocused research effort. Progress in these programs could create value through clinical advancement, regulatory approval, or eventual partnering.

Bears Say

Pre-Revenue Business

The absence of meaningful revenue means Cardiol has not yet demonstrated commercial demand or an operating model funded by customers. Until a candidate is approved and launched, financial performance will remain dependent on clinical progress rather than recurring product sales.

Persistent Cash Burn

Sustained negative operating and free cash flow shows that ongoing research and operations consume substantial cash. Because cash burn closely mirrors accounting losses, the company may need continued capital access to maintain development activity over the coming quarters.

Funding Dependence

Reliance on external financing makes clinical execution sensitive to the company’s ability to raise capital on acceptable terms. Continued funding needs can dilute existing ownership or constrain the pace of trials, regulatory work, and pipeline investment.

Cardiol Therapeutics News

CT9 FAQ

What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was €0.73 and its highest was €1.95 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is €108.09M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 3 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 12, 2026. The company reported -€0.032 earnings per share for the quarter, beating the consensus estimate of -€0.062 by €0.03.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 120,660,446 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -€0.032 in its last earnings report, beating expectations of -€0.062. Following the earnings report the stock price went up 1.634%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in DE:CT9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology